Press Releases Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Market Closed - London S.E. Other stock markets 09:05:09 10/05/2024 pm IST			5-day change	1st Jan Change
7.88 ^GBX	+1.03%		-1.50%	-71.86%

03/04	Oxford BioDynamics reaches "important milestone" with new laboratory	AN
03/04	Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oxford BioDynamics Plc - Bupa UK to cover EpiSwitch CiRT for customers with cancer	19/23/19	AQ
Bupa UK to cover EpiSwitch® CiRT for customers with cancer	18/23/18	BU
Oxford BioDynamics receives reimbursement code for EpiSwitch Prostate Screening Test	04/23/04	AQ
Oxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test	03/23/03	BU
Oxford Biodynamics launches the 94% accurate EpiSwitch Prostate Screening blood test for men with prostate cancer risk in the US and UK	27/23/27	AQ
Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk	26/23/26	BU
Oxford Biodynamics' Prostate Screening EpiSwitch blood test significantly enhances overall detection accuracy for at risk men	07/23/07	AQ
Oxford BioDynamics’ Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy For At Risk Men	06/23/06	BU
Massachusetts General Hospital reports results of Interim Analysis from REFINE-ALS biomarker trial by Mitsubishi Tanabe Pharma USA, utilizing Oxford Biodynamics' EpiSwitch platform for prognostic stratification of fast progression ALS	19/22/19	AQ
Oxford BioDynamics in San Francisco for the 41st Annual J.P. Morgan Healthcare Conference	19/22/19	BU
Massachusetts General Hospital Reports Results of Interim Analysis from REFINE-ALS Biomarker Trial by Mitsubishi Tanabe Pharma USA, Utilizing Oxford Biodynamics’ EpiSwitch® Platform for Prognostic Stratification of Fast Progression ALS	16/22/16	BU
Prominent oncologist to discuss advantages of Oxford BioDynamics	22/22/22	AQ
Oxford BioDynamics’s Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) Now Available in the UK	21/22/21	BU
Oxford BioDynamics Announces US Launch of Its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for Oncology	25/22/25	BU
Oxford BioDynamics : Awarded US FNIH Grant to Apply EpiSwitch® Immune Health Test for Improved Prediction of Patient Response to Immune Checkpoint Inhibitor (ICI) Cancer Therapies	31/21/31	BU
Oxford BioDynamics : The Prime Meridian Group Collaborates With Oxford BioDynamics Plc On Market Research	19/21/19	PR
Oxford BioDynamics : Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch™ Disease Severity Program for COVID-19	02/20/02	BU
Oxford BioDynamics : Advances EpiSwitch™ Disease Severity Program for COVID-19 with Top US Academic Health Center, Oregon Health & Science University	28/20/28	BU
Oxford BioDynamics : Board transition	03/20/03	PU
Oxford BioDynamics : Business update and notice of interim results	21/20/21	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Press Releases

Filters